Assessment of Coagulation Profile in Adults Vaccinated Against SARS‐CoV‐2 (COVID-19) in Qena Governorate

Abstract

Background: Egypt is just one of many countries around the world that have approved or granted emergency use authorization (EUA) for six different vaccines to prevent COVID-19: Moderna (mRNA-1273), Oxford/AstraZeneca (ChAdOx1 nCoV-19), Janssen (Ad26.COV2. S), Pfizer BioNTech (BNT162b2), Sinopharm COVID-19 vaccine and Sinovac-CoronaVac COVID-19 vaccine. Objectives: to evaluate the platelet count and blood coagulation profile in COVID-19 vaccine recipients. Patients and methods: this cross-sectional study was at Qena University Hospital and Clinical Pathology Departments involving 400 adult individuals with male to female ratio 1:1 vaccinated against COVID-19 over 6 months from 1/12/2021 to 1/6/2022: 135(33.8%) received Sinopharm vaccine, 123(30.8%) received Sinovac vaccine, 68(17%) received Pfizer vaccine, 51(12.8%) received AstraZeneca vaccine, 12(3%) received Moderna vaccine, and 11(2.8%) received Janssen vaccine. Results: the mean age of 39.75 ± 13.56 years with a range 18-95 years, the mean platelets count was 229-487 x103/mm3 with a range 280.56±96.62 x103/mm3, the mean value of PT was 13.02±0.7 sec and ranged between 12-16.8 sec, the mean value of PTT was 30.09±3.45 sec and ranged between 24-50 sec, the mean value of D-dimer was 0.35±0.13 mg/l and ranged between 0.19-0.57 mg/l. There were insignificant differences in all types of vaccinations concerning the platelet count, D-dimer, PT, PTT, and INR. Conclusion: Vaccination versus SARS-CoV-2 remains crucial for controlling the COVID-19 pandemic. There is no significant difference in all types of vaccinations concerning D-dimer, PT, PTT, and INR or concerning platelet count.

Keywords

• egypt astrazeneca vaccine janssen vaccine
• moderna vaccine pfizer vaccine